MHRA approves adapted Nuvaxovid JN.1 COVID-19 vaccines for adults and children aged 12 plus

HM Government

Twitter

Facebook

email

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved an adapted version of the Nuvaxovid COVID-19 vaccine that targets the Omicron JN.1 COVID-19 subvariant.

Follow this news feed:

Security guard with fake licence jailed after stealing from hospital 11 incorporated owners fined a total of $32,700 for failing to conduct annual inspections of fire service installations or equipment on their premises

Leave a Reply Cancel reply